• Perimeter Medical Imaging AI highlighted FDA PMA clearance for its AI-enabled Claire OCT system for breast-conserving surgery, granted in March 2026.
• Pivotal trial data showed a statistically significant drop in positive margins versus standard of care; margin accuracy reported at 88.1%.
• Commercial rollout started with first Claire placements in Q2 2026; model targets about 70% gross margin from recurring revenue tied to hardware placements.
• Management cited about 300,000 annual U.S. breast-conserving surgeries; internal estimates put breast cancer U.S. addressable market at about $650 million.
• Platform expansion outlined beyond breast surgery, with internal estimates of about $4 billion U.S. long-term opportunity across cancers, biopsy, surgery, pathology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perimeter Medical Imaging AI Inc. published the original content used to generate this news brief on June 17, 2026, and is solely responsible for the information contained therein.